Catalyst Dossier · compiled by CeliA 🧫
EARTH LIFE SCIENCES INC (CLTS)
Services-Detective, Guard & Armored Car Services · market cap $430,723
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
19
programs
Upcoming events
4
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-15 (est.)Phase 2 · Androgen Deprivation Therapy (ADT) +/- bicalutamideimp 7/10
- 2026-12-31 (est.)Phase 2 · Arm A: 177Lu rhPSMA-10.1imp 7/10
- 2027-05-01 (est.)Phase 2 · Flotufolastat F18imp 7/10
- 2027-09-05 (est.)Phase 2 · 18F-rhPSMA-7.3 (Posluma)imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| [18F]FPyQCP | Phase 2 | Colorectal Cancer |
| rhPSMA-7.3 (18F) Injection | Phase 3 | Prostate Cancer |
| 18F fluciclovine | Phase 3 | Brain Metastases |
| 18F-Fluciclovine PET CT | Phase 3 | Cancer of the Prostate |
| Lutetium (177Lu) rhPSMA-10.1 Injection | Phase 2 | Prostate Cancer |
| [68Ga]BED003 | Phase 2 | Colorectal Cancer |
| Fluorine F 18 Flotufolastat | Phase 2 | Prostate Carcinoma |
| Arm A: 177Lu rhPSMA-10.1 | Phase 2 | Prostate Cancer |
| 18F-rhPSMA-7.3 (Posluma) | Phase 2 | Prostate Cancer (Post Prostatectomy) |
| 18F-fluciclovine PET Scan | Phase 2 | Metastatic Castration-resistant Prostate Cancer |
| FACBC PET-CT | Phase 2 | Prostate Cancer |
| Androgen Deprivation Therapy (ADT) +/- bicalutamide | Phase 2 | Intermediate Risk Prostate Cancer |
| 18F-Fluciclovine | Phase 2 | Brain Metastases |
| Flotufolastat F18 | Phase 2 | Prostatic Neoplasms |
| Actinium (225Ac) rhPSMA-10.1 | Phase 2 | Metastatic Castration-resistant Prostate Cancer |
| 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent | Phase 3 | Prostate Cancer |
| Furosemide | Phase 2 | Prostate Adenocarcinoma |
| Leuprolide | Phase 2 | Prostate Cancer |
| Prednisone | Phase 2 | Prostate Adenocarcinoma |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CLTS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 19 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.